SEC Comment Letter 0000000000-23-001669 to Armata Pharmaceuticals, Inc. (ARMP)
Armata Pharmaceuticals, Inc.
Date: Feb. 17, 2023 · CIK: 0000921114 · Accession: 0000000000-23-001669
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-269726
Letter
United States securities and exchange commission logo February 17, 2023 Brian Varnum, Ph.D. Chief Executive Officer Armata Pharmaceuticals, Inc. 4503 Glencoe Avenue Marina del Rey, CA 90292 Re:Armata Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed February 13, 2023 File No. 333-269726 Dear Brian Varnum: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Faith Charles, Esq.
Show Raw Text
United States securities and exchange commission logo
February 17, 2023
Brian Varnum, Ph.D.
Chief Executive Officer
Armata Pharmaceuticals, Inc.
4503 Glencoe Avenue
Marina del Rey, CA 90292
Re:Armata Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed February 13, 2023
File No. 333-269726
Dear Brian Varnum:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Faith Charles, Esq.